Zoetis Shares Rally After UBS, Morgan Stanley Adjust Price Targets Ahead of Q3 Results

Zoetis Inc. (NYSE: ZTS) shares rose sharply—approximately 7.5%—to close at $89.20 on November 4, 2026, as the company heads into its third-quarter earnings report amid heightened investor anticipation. This marks a notable pre‑earnings move fueled by recent analyst actions and regulatory progress in its diagnostics and veterinary care portfolio.

Analyst Target Adjustments Spark Market Momentum

In the past week, UBS raised its price target on Zoetis to $85 from $80, while maintaining a Neutral rating, reflecting cautious optimism as the company’s new product contributes to investor sentiment. Simultaneously, Morgan Stanley lowered its target to $82 from $85 but maintained its Overweight rating, signaling ongoing strategic confidence despite tempering expectations. These shifts align with the stock’s strong rally—adding clarity to forward outlooks. Both changes occurred within the past 8 days.

FDA Approval of Convenia RTU Supports Product Momentum

Zoetis also gained a regulatory boost when the U.S. Food and Drug Administration approved Convenia RTU for Dogs—a ready-to-use, single-injection antibiotic designed to treat bacterial skin infections in dogs. This approval, announced approximately two weeks ago, enhances the company’s companion‑animal diagnostics and treatment offerings through a high-convenience solution.

Earnings Report in Focus Amid U.S. Pet Health Weakness

The stock’s recent rally comes ahead of Zoetis’s Q3 earnings announcement, expected November 5. Market commentary highlights U.S. pet-health weakness—particularly in clinic visits, dermatology prescriptions, and parasiticide volumes—as potential headwinds. Nonetheless, the new FDA‑approved product and international and livestock segment resilience could offer upside.

What Investors Should Watch

• Q3 results: Key metrics include U.S. versus international performance, and initial revenue contribution from Convenia RTU.
• Analyst revisions: Any new earnings or guidance updates may prompt further revisions to analyst targets.
• Diagnostic services growth: Signs of momentum in genetic tests or biodevices could reinforce Zoetis’s strategic positioning in diagnostics.

Zoetis’s share-price surge reflects investor optimism in its innovation pipeline, particularly Convenia RTU’s FDA approval, while weighing pending Q3 results against broader pet-health sector pressures. With the earnings report imminent, the stock’s near‑term direction hinges on operational performance validation and guidance clarity.

Verified market data: ZTS closed at $89.20 on November 4, 2026, up approximately 7.5% that day.

If you’d like a post‑earnings follow-up or deeper analysis of Zoetis’s diagnostics segment, I’d be glad to help.